GlobeNewswire: Galimedix Therapeutics, Inc. Contains the last 10 of 14 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:55:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2842923/0/en/Galimedix-Therapeutics-presents-new-scientific-data-showing-promising-neuroprotective-effects-of-GAL-201-for-the-treatment-of-Alzheimer-s-disease-at-AD-PD-2024.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 20242024-03-08T09:00:00Z<![CDATA[KENSINGTON, Md., March 08, 2024 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announces encouraging data with orally available small molecule GAL-201, showing its neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD (Russ et. al. 2022). The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024: advances in science and therapy).]]>https://www.globenewswire.com/news-release/2023/03/29/2636628/0/en/Th%C3%A9a-Open-Innovation-and-Galimedix-announce-strategic-partnership-to-develop-and-commercialize-GAL-101-a-Phase-2-3-ready-small-molecule-to-treat-ophthalmic-indications-with-high-un.html?f=22&fvtc=4&fvtv=51598Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need2023-03-29T12:00:00Z<![CDATA[CLERMONT FERRAND, France and KENSINGTON, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Théa Open Innovation (“TOI”), a sister company of ophthalmic specialty pharmaceutical company Laboratoires Théa, and Galimedix Therapeutics, Inc. (“Galimedix”), a clinical-stage biotechnology company addressing the cause of neurodegenerative diseases of the eye and central nervous system, announced today that they have signed a licensing agreement. Galimedix will grant TOI exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and oral treatment of dry age-related macular degeneration (AMD), glaucoma and other ophthalmic indications with high unmet medical need, in Europe, the Americas, the Middle East and Africa.]]>https://www.globenewswire.com/news-release/2019/10/29/1936978/0/en/Galimedix-Therapeutics-Inc-s-GAL-101-Gains-from-Target-Validation-by-Positive-Phase-3-Results-of-Biogen-s-Aducanumab.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab2019-10-29T12:00:00Z<![CDATA[KENSINGTON, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain, today announced that the recent positive results of a Phase 3 study in Alzheimer’s disease with Biogen’s aducanumab also validate the target of the company’s lead molecule, GAL-101.]]>https://www.globenewswire.com/news-release/2019/10/21/1932657/0/en/Galimedix-Therapeutics-Inc-To-Present-at-the-BIO-Investor-Summit.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit2019-10-21T13:45:00Z<![CDATA[KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain, today announced that the company’s chief scientific officer, Hermann Russ, M.D., Ph.D., will present and meet with investors at the BIO Investor Summit on October 23, 2019.]]>https://www.globenewswire.com/news-release/2019/10/21/1932545/0/en/Galimedix-Therapeutics-Inc-Appoints-Recognized-Industry-Veteran-Alexander-Gebauer-M-D-Ph-D-as-Executive-Chairman.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman2019-10-21T12:30:00Z<![CDATA[KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain, today announced the appointment of Alexander Gebauer, M.D., Ph.D., as executive chairman of the Board of Directors.]]>https://www.globenewswire.com/news-release/2019/10/08/1926592/0/en/Galimedix-Therapeutics-Inc-To-Present-at-Ophthalmology-Innovation-Summit-During-the-American-Academy-of-Ophthalmology-Meeting.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting2019-10-08T13:35:00Z<![CDATA[New Preclinical Data Demonstrate Restoration of Lost Neuronal Function With GAL-101 in vitro, Could Translate into a Better Vision in Glaucoma and dry AMD Patients New Preclinical Data Demonstrate Restoration of Lost Neuronal Function With GAL-101 in vitro, Could Translate into a Better Vision in Glaucoma and dry AMD Patients]]>https://www.globenewswire.com/news-release/2019/05/08/1819313/0/en/Preclinical-Studies-Demonstrate-Galimedix-Therapeutics-Investigational-Compound-GAL-101-Shows-Neuroprotective-Effect-from-Toxic-Amyloid-Beta-in-Dry-AMD-and-Glaucoma-Models.html?f=22&fvtc=4&fvtv=51598Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models2019-05-08T12:00:00Z<![CDATA[Poster Presented at the Association for Research in Vision and Ophthalmology Annual Meeting Poster Presented at the Association for Research in Vision and Ophthalmology Annual Meeting]]>https://www.globenewswire.com/news-release/2019/05/06/1817298/0/en/Galimedix-Inc-Appoints-Renowned-Industry-Veteran-and-Innovator-in-the-Field-of-Ophthalmology-Thomas-Hohman-Ph-D-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=51598Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors2019-05-06T11:00:00Z<![CDATA[KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the appointment of Thomas Hohman, Ph.D., an established industry leader who oversaw the development of multiple ophthalmology therapies for more than 30 years, to its Board of Directors.]]>https://www.globenewswire.com/news-release/2019/02/11/1716614/0/en/Galimedix-Therapeutics-to-Present-at-the-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics to Present at the BIO CEO & Investor Conference2019-02-11T13:30:00Z<![CDATA[KENSINGTON, Md. and SHORASHIM, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced Andrew Pearlman, Ph.D., Galimedix’s CEO, will present at the BIO CEO & Investor Conference in New York City. Dr. Pearlman’s presentation will be on Tuesday, February 12, 2019 at 11:00 AM ET in the Chelsea Room. The conference is being held at the New York Marriott Marquis in New York City.]]>https://www.globenewswire.com/news-release/2019/02/06/1711498/0/en/Galimedix-Therapeutics-Presents-Data-Showing-Safety-Tolerability-and-Potential-for-Efficacy-of-Its-Investigational-Eyedrops-Containing-GAL-101-at-Glaucoma-360-Conference.html?f=22&fvtc=4&fvtv=51598Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference2019-02-06T14:35:00Z<![CDATA[KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which, in animal models caused sustained prevention of misfolded amyloid beta molecules from aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. The presentation also included positive safety and tolerability data from the company’s Phase 1 study in both healthy and glaucoma patients. These data were presented at the Glaucoma 360 conference on February 1, 2019 in San Francisco by the company’s chief scientific officer, Hermann Russ, M.D., Ph.D.]]>